Cloudbreak Pharma Announces Final Patient Visit for 12-Month Efficacy Endpoint in Phase 3 Study of CBT-001 as a Potential Treatment for Pterygium
Milestone achievement advances potential first FDA-approved disease-modifying therapy for pterygium, a condition affecting just under one billion people globally, including 15 million people in the U.S. Topline data anticipated in Q3 2026
Milestone achievement advances potential first FDA-approved disease-modifying therapy for pterygium, a condition affecting just under one billion people globally, including 15 million people in the U.S.
Topline data anticipated in Q3 2026
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.